Dova Pharmaceuticals Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Companyâ€™s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD). The Companyâ€™s product candidate, avatrombopag is an orally administered thrombopoietin receptor agonist, or TPO-RA. The Company has completed pivotal Phase 3 clinical trials that evaluated avatrombopag for the treatment of thrombocytopenia in patients with CLD. The Company has not generated any revenue.

Employees

Sector

Biotechnology & Medical Research

More about the company

Delayed Nasdaq Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-0.07%	+269.92%

19-12-09	Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study - Core and Extension Phase - with Avatrombopag	CI
19-12-09	Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study Core and Extension Phase	CI

Market Cap	808M 695M 640M 600M 1.13B 76.8B 1.14B 7.59B 2.95B 37.35B 3.03B 2.97B 129B	P/E Ratio 2017	-20.6x	P/E Ratio 2018	-2.92x
Enterprise Value	723M 623M 573M 538M 1.01B 68.78B 1.02B 6.79B 2.64B 33.45B 2.71B 2.66B 116B	EV / Sales 2017	-	EV / Sales 2018	12,500,634x
Free-Float	48.06%	Yield 2017 *	-	Yield 2018	-

19-12-09	Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study - Core and Extension Phase - with Avatrombopag	CI
19-12-09	Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study Core and Extension Phase	CI
19-12-09	Dova Pharmaceuticals Demonstrates Cost-Effectiveness of Doptelet (Avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease	CI
19-12-05	Sobi and Dova Pharmaceuticals to Present New Data from Studies with Avatrombopag for the Treatment of Thrombocytopenia in Adult Patients with Chronic Liver Disease as Well as Patients with Chronic Immune Thrombocytopenia	CI
19-11-13	Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from NASDAQ Composite Index	CI
19-11-12	Dova Pharmaceuticals, Inc. Announces Executive Changes	CI
19-11-12	Dova Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI
19-11-11	Swedish Orphan Biovitrum AB (OM:SOBI) completed the acquisition of Dova Pharmaceuticals, Inc. from Paul B. Manning, Sean Stalfort and other shareholders.	CI
19-11-11	Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from S&P TMI Index	CI
19-11-11	Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from S&P Global BMI Index	CI
19-11-11	Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from NASDAQ Biotechnology Index	CI
19-09-29	Swedish Orphan Biovitrum AB (OM:SOBI) entered into a definitive agreement to acquire Dova Pharmaceuticals, Inc. from Paul B. Manning, Sean Stalfort, and other shareholders for approximately $790 million.	CI
19-08-06	Dova Pharmaceuticals, Inc., Q2 2019 Earnings Call, Aug 06, 2019

19-10-04	WeissLaw LLP Investigates Dova Pharmaceuticals, Inc.	PR
19-09-30	Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) on Behalf of Dova Shareholders and Encourages Dova Investors to Contact the Firm	PR
19-09-30	Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Dova Pharmaceuticals, Inc. has obtained a Fair Price in its sale to Swedish Orphan Biovitrum AB	PR
19-09-30	Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi)	GL
19-09-25	Dova Pharmaceuticals to Present at 2019 Cantor Global Healthcare Conference	GL

Dova Pharmaceuticals, Inc. Stock

Stocks

DOVA

US25985T1025

Biotechnology & Medical Research

Valuation: Dova Pharmaceuticals, Inc.

Latest news : Dova Pharmaceuticals, Inc.

Press Releases: Dova Pharmaceuticals, Inc.

Managers and Directors: Dova Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Manager	Title	Age	Since
Lee F. Allen CTO	Chief Tech/Sci/R&D Officer	74	2017-03-31
Stephen Crane SAM	Sales & Marketing	-	-
Caroline Diaz LAW	General Counsel	-	-

Director	Title	Age	Since
Henrik Stenqvist BRD	Director/Board Member	59	2019-11-11
Per Richard Torbjörn Hallberg BRD	Director/Board Member	57	2019-11-11
Guido Oelkers BRD	Director/Board Member	61	2019-11-11

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DOVA PHARMACEUTICALS, INC.	-.--%	-0.07%	-	-	808M
ARGENX SE	+1.03%	+2.30%	+55.91%	+114.22%	56.42B
WUXI APPTEC CO., LTD.	+2.72%	+3.26%	+46.05%	+44.91%	44.54B
BIONTECH SE	+1.12%	+2.79%	-15.04%	-21.68%	22.9B
INSMED INCORPORATED	+1.17%	+3.85%	-0.89%	+403.86%	21.21B
WUXI BIOLOGICS (CAYMAN) INC.	+3.81%	-5.07%	+11.00%	-30.62%	16.4B
GENMAB A/S	+0.15%	+2.24%	+9.32%	-39.30%	15.4B
EXELIXIS, INC.	-0.69%	+0.82%	+27.75%	+176.72%	13.35B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5.27%	+5.54%	+19.65%	-	12.36B
PHARMAESSENTIA CORPORATION	+1.61%	+1.28%	+95.75%	+205.26%	11.15B
Average	+1.62%	+1.87%	+27.72%	+106.67%	21.45B
Weighted average by Cap.	+1.72%	+2.36%	+32.04%	+99.60%

	2017	2018
Net sales	-	10.36 8.91 8.21 7.7 14.45 984.76 14.62 97.28 37.82 478.86 38.86 38.03 1.65K
Net income	-29.96M -25.79M -23.75M -22.27M -41.8M -2.85B -42.28M -281M -109M -1.39B -112M -110M -4.79B	-72.28M -62.22M -57.31M -53.74M -101M -6.87B -102M -679M -264M -3.34B -271M -265M -11.55B
Net Debt	-64.53M -55.55M -51.17M -47.98M -90.04M -6.14B -91.09M -606M -236M -2.98B -242M -237M -10.31B	-84.34M -72.61M -66.88M -62.7M -118M -8.02B -119M -792M -308M -3.9B -316M -310M -13.47B